Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Familial platelet disorder with predisposition to acute myelogenous leukaemia (FPD/AML, MIM 601399) is an autosomal dominant disorder characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukaemia (AML). Informative recombination events in 6 FPD/AML pedigrees with evidence of linkage to markers on chromosome 21q identified an 880-kb interval containing the disease gene. Mutational analysis of regional candidate genes showed nonsense mutations or intragenic deletion of one allele of the haematopoietic transcription factor CBFA2 (formerly AML1) that co-segregated with the disease in four FPD/AML pedigrees. We identified heterozygous CBFA2 missense mutations that co-segregated with the disease in the remaining two FPD/AML pedigrees at phylogenetically conserved amino acids R166 and R201, respectively. Analysis of bone marrow or peripheral blood cells from affected FPD/AML individuals showed a decrement in megakaryocyte colony formation, demonstrating that CBFA2 dosage affects megakaryopoiesis. Our findings support a model for FPD/AML in which haploinsufficiency of CBFA2 causes an autosomal dominant congenital platelet defect and predisposes to the acquisition of additional mutations that cause leukaemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The transcription factor RUNX-1 plays a key role in megakaryocyte differentiation and is mutated in cases of myelodysplastic syndrome and leukemia.”
From Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development. (2009) · cites this paper as [48]
In the citing paper
“Germ line mutations in RUNX-1 cause familial platelet disorder with the propensity to develop acute myelogenous leukemia (FPD/AML), a rare autosomal dominant disorder characterized by quantitative and qualitative platelet defects and a high incidence of developing myelodysplastic syndrome (MDS) and leukemia”
From Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development. (2009) · cites this paper as [48]
Citations
Cites
Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856
de Thé, H., Chomienne, C., Lanotte, M., Degos, L., & Dejean, A. (1990) · Nature · doi:10.1038/347558a0 · Cited by 1,355 · cited 1×
“Fusion of PDGF Receptor β to a novel ETS-like gene, TEL, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.”
BackgroundWang, Q., Stacy, T., Binder, M., Marin-Padilla, M., Sharpe, A. H., & Speck, N. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3444 · Cited by 1,178
Self-citationGolub, T. R., Barker, G. F., Lovett, M., & Gilliland, D. G. (1994) · Cell · doi:10.1016/0092-8674(94)90322-0 · Cited by 1,155
Self-citationOncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis.
Weinberg, R. A. (1989) · PubMed · Cited by 949
The murine gene p27Kip1 is haplo-insufficient for tumour suppression
Fero, M. L., Randel, E., Gurley, K. E., Roberts, J. M., & Kemp, C. J. (1998) · Nature · doi:10.1038/24179 · Cited by 784
Fusion Between Transcription Factor CBFβ/PEBP2β and a Myosin Heavy Chain in Acute Myeloid Leukemia
Liu, P., Tarlé, S. A., Hajra, A., Claxton, D. F., Marlton, P., Freedman, M., Siciliano, M. J., & Collins, F. S. (1993) · Science · doi:10.1126/science.8351518 · Cited by 732 · cited 1×
“; the CBFB / MYH11 fusion associated with inv(16) myelomonocytic leukaemia with eosinophili”
BackgroundFusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia.
Golub, T. R., Barker, G. F., Bohlander, S. K., Hiebert, S. W., Ward, D. C., Bray-Ward, P., Morgan, E., Raimondi, S. C., Rowley, J. D., & Gilliland, D. G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4917 · Cited by 704
Self-citationShivdasani, R. A., Rosenblatt, M. F., Zucker-Franklin, D., Jackson, C. W., Hunt, P., Saris, C. J. M., & Orkin, S. H. (1995) · Cell · doi:10.1016/0092-8674(95)90531-6 · Cited by 693 · cited 1×
“It is notable that mice hemizygous for genes required for megakaryopoiesis, such as Gata1 , Nfe2 and fog , have apparent platelet defect”
BackgroundShivdasani, R. A., Fujiwara, Y., McDevitt, M. A., & Orkin, S. H. (1997) · The EMBO Journal · doi:10.1093/emboj/16.13.3965 · Cited by 674 · cited 1×
“It is notable that mice hemizygous for genes required for megakaryopoiesis, such as Gata1 , Nfe2 and fog , have apparent platelet defect”
Background
Cited by
Items 701–800 of 1,000
Trottier, A. M., Feurstein, S. K., & Godley, L. A. (2024) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2024.101537 · Cited by 15
Jayne, N. D., Liang, Z., Lim, D., Chen, P. B., Diaz, C., Arimoto, K., Xia, L., Liu, M., Ren, B., Fu, X., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011484 · Cited by 13
Bagla, S., Regling, K., Wakeling, E. N., Gadgeel, M., Buck, S. A., Zaidi, A. U., Flore, L. A., Chicka, M. C., Schiffer, C. A., Chitlur, M., et al. (2020) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2020.1814463 · Cited by 13
“The first report on haploinsufficiency of RUNX1 was published in 1999 by Song et al, and since then almost 75 affected families have been reported.(3,4) The overall risk of myeloid malignancy in patients with RUNX1-FPD is 35%-40% with an average onset age of 33 years.”
BackgroundKrajnović, M., Kožik, B., Božović, A., & Jovanović-Ćupić, S. (2023) · Cells · doi:10.3390/cells12182303 · Cited by 13
The role of aberrant transcription factor in the progression of chronic myeloid leukemia
Zhang, S. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802163305 · Cited by 15
Cancer in a dish: progress using stem cells as a platform for cancer research.
Liu, M., Tu, J., Gingold, J. A., Kong, C. S. L., & Lee, D. (2018) · Europe PMC (PubMed Central) · Cited by 14
Pediatric Myelodysplastic Syndromes
Patel, S. S. (2021) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2021.03.015 · Cited by 13
Engvall, M., Karlsson, Y., Kuchinskaya, E., Jörnegren, Å., Mathot, L., Pandzic, T., Palle, J., Ljungström, V., Cavelier, L. B., Lindberg, E. H., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2067997 · Cited by 13
“Pathogenic germline variants in RUNX1 were first reported in 1999 in six pedigrees, one of which was an intragenic deletion of exons 4–5, while the remaining were either nonsense (n1⁄4 3) or missense mutations (n1⁄4 2) located in the RUNT domain [10].”
BackgroundChromosome 21: a small land of fascinating disorders with unknown pathophysiology
Antonarakis, S. E., Lyle, R., Deutsch, S., & Reymond, A. (2002) · The International Journal of Developmental Biology · doi:10.1387/ijdb.11902692 · Cited by 14
“(Song et al., 1999) (OMIM 601399), and COL18A1 for Knobloch syndrome (Sertie et al., 2000) (OMIM 267750) have been identified.”
Histologic and molecular characterizations of megakaryocytic leukemia in mice
Hao, X., Shin, M. S., Zhou, J. X., Lee, C. H., Chen, Q., Naghashfar, Z., Hartley, J. W., Fredrickson, T. N., Ward, J. M., & Morse, H. C. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.08.021 · Cited by 13
Gribble, S. M., Reid, A. G., Bench, A. J., Huntly, B. J. P., Grace, C. D., Green, A. R., & Nacheva, E. P. (2003) · Leukemia · doi:10.1038/sj.leu.2402980 · Cited by 13
Ok, C. Y., Leventaki, V., Wang, S. A., Dinardo, C. D., Medeiros, L. J., & Konoplev, S. N. (2016) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqv080 · Cited by 12
“Several missense, nonsense, and frameshift mutations; intragenic deletions; and intragenic duplication have been reported in patients with FDP/MM.1,8-14 FPD/MM was first reported in 1978 by Luddy et al,15 who described a family of three siblings with lifelong history of a bleeding disorder and thrombocytopenia.”
BackgroundInfluentialArray CGH in Human Leukemia: From Somatics to Genetics
van der Veken, L. T., & Buijs, A. (2011) · Cytogenetic and Genome Research · doi:10.1159/000330629 · Cited by 12
“Familial platelet disorder with propensity to AML (FPD/AML; OMIM 601399) with autosomal dominant trait of inheritance was initially reported to be due to germline point mutations or an intragenic deletion of the 21q22 RUNX1 gene [Song et al., 1999; Buijs et al., 2001].”
BackgroundClinical characteristics and platelet phenotype in a family withRUNX1mutated thrombocytopenia
Botero, J. P., Chen, D., Cousin, M. A., Majerus, J. A., Coon, L. M., Kruisselbrink, T., Klee, E. W., Lazaridis, K. N., Pruthi, R. K., & Patnaik, M. M. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1265118 · Cited by 14
“[13] Acquired cytogenetic abnormalities like trisomy 8 [9] and 5q deletion [7] at the time of clonal evolution have also been reported.”
BackgroundResultInfluentialRUNX1 and CBFβ Mutations and Activities of Their Wild-Type Alleles in AML
Hyde, R. K., Liu, P., & Friedman, A. D. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-3233-2_17 · Cited by 13
Rare germline variant contributions to myeloid malignancy susceptibility
Li, S. T., Wang, J., Wei, R., Shi, R., Ademà, V., Nagata, Y., Kerr, C. M., Kuzmanovic, T., Przychodzen, B. P., Solé, F. G., et al. (2020) · Leukemia · doi:10.1038/s41375-019-0701-8 · Cited by 12
Cytogenetics of acute leukemias
Raimondi, S. C. (2006) · Cambridge University Press eBooks · doi:10.1017/cbo9780511471001.010 · Cited by 15
Systems Biology of Megakaryocytes
Kaushansky, A., & Kaushansky, K. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-2095-2_4 · Cited by 13
“Its critical role in megakaryopoiesis was established by gene mapping studies in patients with familial platelet disorder/predisposition to AML; such patients, but not their normal family members, display haploinsufficiency of RUNX1, linking the gene to thrombocytopenia [92].”
BackgroundG ENETIC P ROFILE OF A CUTE M YELOID L EUKEMIA
Mecucci, C., Rosati, R., & Starza, R. L. (2002) · Reviews in Clinical and Experimental Hematology · doi:10.1046/j.1468-0734.2002.00060.x · Cited by 13
Roles of AML 1/ RUNX 1 in T‐cell malignancy induced by loss of p53
Shimizu, K., Yamagata, K., Kurokawa, M., Mizutani, S., Tsunematsu, Y., & Kitabayashi, I. (2013) · Cancer Science · doi:10.1111/cas.12199 · Cited by 16
Bardet, V., Couque, N., Cattolico, L., Hetet, G., Devaux, I., Duprat, S., Gressin, L., VILMER, E., Cavé, H., & Grandchamp, B. (2001) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10014 · Cited by 12
“Haploinsufficiency of CBFA2 predisposes to acute myelogenous leukemia, whereas the second allele is not mutated in malignant cells (Song et al., 1999).”
BackgroundLee, B., Zhou, Y., Bresciani, E., Özkaya, N., Dulau-Florea, A., Carrington, B., Shin, T., Baena, V., Syed, Z. A., Hong, S. G., et al. (2022) · Blood · doi:10.1182/blood.2022018193 · Cited by 11
Guan, L., Voora, D., Myers, R. A., Carpio‐Cano, F. D., & Rao, A. K. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.07.032 · Cited by 11
Heritability of Hematologic Malignancies: From Pedigrees to Genomics
Churpek, J. E., & Onel, K. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.06.001 · Cited by 11
“To date, more than 30 families have been described in which nearly all affected members have heterozygous mutations of RUNX1, a transcription factor involved in regulation of hematopoiesis, on chromosome 21q22.(157,158) Significant clinical hetero-”
BackgroundAbsence of somatic mutations within the Runt domain of AML2/RUNX3 in acute myeloid leukaemia
Otto, F., Stock, M., Fliegauf, M., Fenaux, P., Preudhomme, C., & Lübbert, M. (2003) · Leukemia · doi:10.1038/sj.leu.2403007 · Cited by 11
Rao, A. K., & Poncz, M. (2017) · Haemophilia · doi:10.1111/hae.13280 · Cited by 11
Self-citationCongenital Disorders of Platelet Function and Number
Sharma, R., Botero, J. P., & Jobe, S. M. (2018) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2018.02.009 · Cited by 14
Jalagadugula, G. S., Mao, G., Goldfinger, L. E., Wurtzel, J. G. T., Carpio‐Cano, F. D., Lambert, M. P., Estevez, B., French, D. L., Poncz, M., & Rao, A. K. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006945 · Cited by 12
“The RUNT-related transcription factor 1, RUNX1 (also called AML1 or CBFA2), is a master regulator of hematopoiesis and a major player in megakaryocyte/platelet biology.15-19 Human monoallelic RUNX1 mutations are associated with familial thrombocytopenia, platelet a-granule and dense granule deficiencies, impaired plat…”
BackgroundSelf-citationSiblings presenting with progressive congenital aleukemic leukemia cutis
Agrawal, A. K., Guo, H., & Golden, C. B. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23053 · Cited by 11
Draper, J. E., Sroczyńska, P., Fadlullah, M. Z. H., Patel, R., Newton, G., Breitwieser, W., Kouskoff, V., & Lacaud, G. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007127 · Cited by 11
“To demonstrate the application of our fetal liver myeloid progenitor scheme, we analyzed the impact of deleting Runx1 (a mutation which causes a megakaryocytic differentiation block comparable to FPD/AML [38,46,48]) on the specification and differentiation of these compartments.”
BackgroundMethodDuarte, B. K. L., Yamaguti-Hayakawa, G. G., Medina, S. S., Siqueira, L. H., Snetsinger, B., Costa, F. F., Rauh, M. J., & Ozelo, M. C. (2019) · British Journal of Haematology · doi:10.1111/bjh.15990 · Cited by 11
“RUNX1 was the first gene associated with a predisposition to myeloid malignancies (MM) (Song et al, 1999).”
BackgroundGenetic predisposition in acute leukaemia
Wiggins, M., & Stevenson, W. S. (2020) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13173 · Cited by 11
Validation and clinical application of transactivation assays forRUNX1variant classification
Decker, M., Agarwal, A., Benneche, A., Churpek, J. E., Duployez, N., DuVall, A. S., Ernst, M. P. T., Förster, A., Høberg‐Vetti, H., Hofmann, I., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006161 · Cited by 11
Serrano, E., Carnicer, M. J., Lasa, A., Orantes, V., Peña, J., Brunet, S., Aventin, A. M., Sierra, J., & Nomdedeu, J. F. (2008) · Leukemia Research · doi:10.1016/j.leukres.2007.11.038 · Cited by 11
Transcription factors in hematopoietic malignancies
Gery, S., & Koeffler, H. P. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.012 · Cited by 11
Dror, Y. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(02)01078-0 · Cited by 11
Wu, X., Deng, J., Zhang, N., Liu, X., Zheng, X., Yan, T., Ye, W., & Gong, Y. (2022) · BMC Cancer · doi:10.1186/s12885-022-09347-0 · Cited by 10
“first reported that germline RUNX1 mutation was associated with familial platelet disorder predisposition to acute myeloid leukemia (FPD/AML) [2].”
BackgroundPin1‐Mediated Prolyl Isomerization of Runx1 Affects PU.1 Expression in Pre‐Monocytes
Islam, R., Yoon, W., Woo, K. M., Baek, J., & Ryoo, H. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24462 · Cited by 11
“In humans, haploinsufficiency of RUNX1 is associated with an increase in myeloid progenitors, platelet dysfunction, familial thrombocytopenia, splenomegaly and a predisposition to acute leukemia (Song et al., 1999; Growney et al., 2005; Putz et al., 2006).”
Autotransplants in older multiple myeloma patients: hype or hope in the era of novel agents?
Engelhardt, M. M., Ihorst, G., Caers, J., Günther, A., & Wäsch, R. (2016) · Haematologica · doi:10.3324/haematol.2016.154807 · Cited by 10
Germline Predisposition to Myeloid Neoplasms
Obiorah, I. E., Upadhyaya, K., & Calvo, K. R. (2023) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2023.06.004 · Cited by 10
Ahmad, M. H., Hegde, M., Wong, W. J., Mohammadhosseini, M., Garrett, L. J., Carrascoso, A., Issac, N. G., Ebert, B. L., Silva, J. C., Pihan, G. A., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010398 · Cited by 10
Jiang, Y., Shu, Y., Shi, Y., Li, L., Yuan, F., & Ren, H. (2014) · BioMed Research International · doi:10.1155/2014/371397 · Cited by 11
“RUNX1 (see row 6 of Table 2), better known as AML1, plays a critical role in hematopoietic development [92].”
BackgroundAcute Myeloid Leukemia in Adults
Appelbaum, F. R. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50108-1 · Cited by 11
Wang, Y., Huo, T., Tseng, Y.-J., Dang, L., Yu, Z., Yu, W., Foulks, Z., Murdaugh, R. L., Ludtke, S. J., Nakada, D., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03009-4 · Cited by 10
Inherited Bone Marrow Failure Syndromes
Canham, L. E., & de Jong, J. L. O. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00131-1 · Cited by 10
Richter, L. E., Wang, Y., & Hyde, R. K. (2016) · Oncotarget · doi:10.18632/oncotarget.11357 · Cited by 12
“Heterozygous germline mutations in RUNX1 cause Familial Platelet disorder with a predisposition to AML (FPD-AML) [63, 64].”
BackgroundRUNX1 Mutations in the Leukemic Progression of Severe Congenital Neutropenia.
Olofsen, P. A., & Touw, I. P. (2020) · PubMed · doi:10.14348/molcells.2020.0010 · Cited by 16
“These germline mutations are similar to those acquired in MDS/AML (Song et al., 1999).”
BackgroundC-terminal RUNX1 mutation in familial platelet disorder with predisposition to myeloid malignancies
Kozubík, K. S., Radová, L., Pešová, M., Réblová, K., Trizuljak, J., Plevová, K., Fiamoli, V., Gumulec, J., Urbánková, H., Szotkowski, T., et al. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2514-3 · Cited by 10
Heterozygous loss of Srp72 in mice is not associated with major hematological phenotypes
D’Altri, T., Schuster, M. B., Wenzel, A., & Porse, B. T. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13286 · Cited by 10
Shikami, M., Miwa, H., Nishii, K., Kyo, T., Tanaka, I., Shiku, H., Kita, K., & Nitta, M. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.08.007 · Cited by 11
Steer, E. J., Goldman, J. M., & Cross, N. C. P. (2001) · Leukemia · doi:10.1038/sj.leu.2402062 · Cited by 10
Marín‐Quilez, A., Sánchez‐Fuentes, A., Zamora‐Cánovas, A., Gómez‐González, P. L., Díaz‐Ajenjo, L., Benito, R., Rodríguez‐Alén, A., Sevivas, T. S., Murciano, T., Murillo, L., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.70001 · Cited by 9
Interface-guided phenotyping of coding variants in the transcription factor RUNX1
Öztürk, K., Panwala, R., Sheen, J., Ford, K. M., Jayne, N. D., Portell, A. J., Zhang, D., Hütter, S., Haferlach, T., Ideker, T., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114436 · Cited by 11
Overt and covert genetic causes of pediatric acute lymphoblastic leukemia
Stoltze, U. K., Junk, S. V., Byrjalsen, A., Cavé, H., Cazzaniga, G., Elitzur, S., Froňková, E., Hjalgrim, L. L., Kuiper, R. P., Lundgren, L., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02535-4 · Cited by 9
Appelmann, I., Linden, T., Rudat, A., Müller‐Tidow, C., Berdel, W. E., & Mesters, R. M. (2009) · Annals of Hematology · doi:10.1007/s00277-009-0722-x · Cited by 9
Clinical utility gene card for: Familial platelet disorder with associated myeloid malignancies
Ripperger, T., Tawana, K., Kratz, C. P., Schlegelberger, B., Fitzgibbon, J., & Steinemann, D. (2016) · European Journal of Human Genetics · doi:10.1038/ejhg.2015.278 · Cited by 9
Addiction toRunx1is partially attenuated by loss of p53 in the Eμ-Myc lymphoma model
Borland, G., Kilbey, A., Hay, J., Gilroy, K. L., Terry, A., Mackay, N. A., Bell, M., McDonald, A., Mills, K., Cameron, E. R., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8554 · Cited by 10
“We also noted little overlap with the mitotic checkpoint signature observed after knockdown of RUNX1 in Kasumi t(8;21) AML cells [31].”
BackgroundInfluentialYoshida, T., Yamasaki, K., Tadagaki, K., Kuwahara, Y., Matsumoto, A., Sofovic, A., Kondo, N., Sakai, T., & Okuda, T. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5296 · Cited by 9
Förster, A., Davenport, C., Duployez, N., Erlacher, M., Ferster, A., Fitzgibbon, J., Göhring, G., Hasle, H., Jongmans, M. C. J., Kolenová, A., et al. (2023) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2023.104727 · Cited by 9
Ito, Y., Osato, M., & Ito, K. (2003) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v32n5sps6 · Cited by 11
Hassan, S., & Smith, M. (2014) · Hematology · doi:10.1179/1024533214z.000000000312 · Cited by 10
The molecular basis of congenital thrombocytopenias: Insights into megakaryopoiesis
Geddis, A. E. (2005) · Hematology · doi:10.1080/10245330512331390401 · Cited by 12
“Mutations in RUNX1, a transcription factor with a critical role in definitive hematopoiesis [19,20] and leukemogenesis [21], have been described in familial platelet disorder with predisposition to acute myelogenous leukemia (FPD/ AML) [22,23].”
BackgroundPutative association of RUNX1 polymorphisms with IgE levels in a Korean population
Chae, S., Park, B. L., Park, C., Ryu, H.-J., Yang, Y.-S., Lee, S. O., Choi, Y. H., Kim, E. M., Uh, S. T., Kim, Y., et al. (2006) · Experimental & Molecular Medicine · doi:10.1038/emm.2006.68 · Cited by 10
Thalidomide in myelodysplastic syndromes
Zorat, F., & Pozzato, G. (2002) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(01)00145-7 · Cited by 9
Golub, T. R. (2007) · Nature · doi:10.1038/446739a · Cited by 9
Ramanan, R., Verstraete, A., Laer, C. V., & Freson, K. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.04.026 · Cited by 8
Gao, G., Moreira, J. D., Das, P., Lin, K., Ge, K., Chen, T., Lu, Y., & Santos, M. A. (2025) · Nature Communications · doi:10.1038/s41467-025-61247-6 · Cited by 8
A POTEntial new gene for thrombocytopenia
Geddis, A. E. (2011) · Blood · doi:10.1182/blood-2011-04-348383 · Cited by 8
Spotlight on FLI1, RUNX1, and platelet dysfunction
Rao, A. K. (2013) · Blood · doi:10.1182/blood-2013-10-533166 · Cited by 9
Update on childhood neutropenia: molecular and clinical advances
Dror, Y., & Sung, L. (2004) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2004.06.013 · Cited by 8
“Many of the inherited marrow failure syndromes are characterized by a propensity for malignant transformation into MDS and AML [90–95].”
BackgroundTumor suppressor gene inactivation in myeloid malignancies
Wong, J. C. Y., Beau, M. M. L., & Shannon, K. (2008) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2008.09.001 · Cited by 9
Escher, R., Wilson, P., Carmichael, C., Suppiah, R., Liu, M., Kavallaris, M., Cannon, P., Michaud, J., & Scott, H. S. (2007) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.02.009 · Cited by 8
A distinct epigenetic signature at targets of a leukemia protein
Rossetti, S., Hoogeveen, A. T., Liang, P., Stanciu, C., van der Spek, P. J., & Sacchi, N. (2007) · BMC Genomics · doi:10.1186/1471-2164-8-38 · Cited by 10
“The identification of this protein network strongly supports the biological data, indicating the occurrence of functional AML1 haploinsufficiency in A16 cells [9].”
BackgroundResultShiga, K., Matsuura, K., Tateda, M., Saijo, S., Ogawa, T., Miyagi, T., & Kobayashi, T. (2004) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.204.163 · Cited by 8
Gene copy number and cell cycle arrest
Ghosh, B., & Bose, I. (2005) · Physical Biology · doi:10.1088/1478-3975/3/1/003 · Cited by 11
“The gene dosage effect is called haploinsufficiency (HI) and has been verified experimentally [11, 12].”
BackgroundHill, A. S., MacCallum, P. K., Young, B. D., & Lillington, D. M. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10277 · Cited by 8
“The RUNX1 gene is located on 21q22 and is involved in the t(8;21) translocation observed in AML M2 and can also be mutated (Osato et al., 1999).”
BackgroundInfluentialGATA2 decommissioning of enhancers: A mechanism to constrain inflammatory signaling
Jung, M. M., Tran, V. L., Xiong, Y., Johnson, K. D., Katsumura, K. R., Liu, P., & Bresnick, E. H. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116344 · Cited by 7
Inducible pluripotent stem cell models to study bone marrow failure and MDS predisposition syndromes
Sahoo, S. S., Khiami, M., & Włodarski, M. W. (2024) · Experimental Hematology · doi:10.1016/j.exphem.2024.104669 · Cited by 8
Banaszak, L. G., Cabral, P. L., Smith-Simmer, K. J., Hassan, A., Brunner, M., Fallon, M. J., Shoger, K., Lovrien, L., Golner, D., Zurbriggen, L. D., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00518 · Cited by 7
Gene therapy by allele selection in a mouse model of beta-thalassemia
Eckardt, S., Leu, N. A., Yanchik, A., Hatada, S., Kyba, M., & McLaughlin, K. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45377 · Cited by 7
Tummala, H., Walne, A. J., Bewicke‐Copley, F., Ellison, A., Pontikos, N., Bridger, M. G., Rio‐Machín, A., Sidhu, J. K., Wang, J., Hasle, H., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002857117 · Cited by 7
“Sp1, ETV6, RUNX1, and ANKRD26 are all expressed in hematopoietic stem cells and megakaryocyte-erythroid progenitors (28–30).”
BackgroundInfluentialMarín‐Quilez, A., García‐Tuñón, I., Fernández-Infante, C., Hernández-Cano, L., Palma‐Barqueros, V., Vuelta, E., Sánchez‐Martín, M., González-Porras, J. R., Guerrero, C., Benito, R., et al. (2021) · Thrombosis and Haemostasis · doi:10.1055/s-0041-1723987 · Cited by 8
An updated account on molecular heterogeneity of acute leukemia.
Rahul, E., Goel, H., Chopra, A., Ranjan, A., Gupta, A. K., Meena, J. P., Bakhshi, S., Misra, A., Hussain, S., Viswanathan, G. K., et al. (2021) · American Journal of Blood Research · Cited by 8
Molecular Genetics of Pediatric Acute Myeloid Leukemia
Krock, B. L., & Oberley, M. J. (2021) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2021.03.014 · Cited by 8
Rubnitz, J. E., Razzouk, B. I., & Ribeiro, R. C. (2006) · Cambridge University Press eBooks · doi:10.1017/cbo9780511471001.020 · Cited by 8
Adult-onset hereditary myeloid malignancy and allogeneic stem cell transplantation
Toya, T., Harada, H., Harada, Y., & Doki, N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.997530 · Cited by 7
“FPD-MM is the first HMMs whose genetic causality was recognized in 1999 (20).”
BackgroundLawrie, A., Stevenson, D. A. J., Doig, T. N., Vickers, M. A., & Culligan, D. J. (2012) · Cancer Genetics · doi:10.1016/j.cancergen.2012.09.001 · Cited by 7
Molecular and Cellular Biology of Platelet Formation: Implications in Health and Disease
Italiano, J. E., & Schulze, H. (2016) · Springer eBooks · doi:10.1007/978-3-319-39562-3 · Cited by 8
Liu, H., Cui, Y. T., Wang, G., Dong, Q., Yao, Y., Li, P., Cao, C., & Liu, X. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.05.001 · Cited by 8
Germ line predisposition to myeloid malignancies appearing in adulthood
Crysandt, M. M., Brings, K., Beier, F., Thiede, C., Brümmendorf, T. H., & Jost, E. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1494566 · Cited by 7
“Studies show that germ line mutations in RUNX1 results in predisposition for MDS and AML as well as T-ALL or B cell malignancies [34,35].”
BackgroundCarraway, H. E., & LaFramboise, T. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101191 · Cited by 7
Mutational Analyses of the AML1 Gene in Patients with Myelodysplastic Syndrome
Imai, Y., Kurokawa, M., Izutsu, K., Hangaishi, A., Maki, K., Ogawa, S., Chiba, S., Mitani, K., & Hirai, H. (2002) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190290012155 · Cited by 7
“Furthermore, it was reported that haploinsufficiency of AML1 caused by the mutations of the AML1 gene in one allele results in familial platelet disorder with predisposition to acute myelogeneous leukemia (FPD/AML) [30].”
BackgroundDyskeratosis congenita: a disorder of telomerase deficiency and its relationship to other diseases
Marrone, A., & Dokal, I. S. (2006) · Expert Review of Dermatology · doi:10.1586/17469872.1.3.463 · Cited by 7
Boyd, V., & McKendry, S. (2012) · European Journal for Research on the Education and Learning of Adults · doi:10.3384/rela.2000-7426.rela0059 · Cited by 8
AML-1 mutations outside the RUNT domain: description of two cases in myeloid malignancies
Carnicer, M. J., Nomdedeu, J. F., Lasa, A., Bellido, M., Aventin, A. M., Baiget, M., & Sierra, J. (2002) · Leukemia · doi:10.1038/sj.leu.2402656 · Cited by 7
Ferrari, T., Weber, B., Pils, S., Harbott, J., & Borkhardt, A. (2001) · Annals of Hematology · doi:10.1007/s002770000238 · Cited by 8
“Finally, a recent report has linked AML-1 to a congenital hematological disorder, the familial thrombocytopenia with predisposition to AML [9].”
BackgroundMethodTyrosyl phosphorylation toggles a Runx1 switch
Neel, B. G., & Speck, N. A. (2012) · Genes & Development · doi:10.1101/gad.198051.112 · Cited by 7
Self-citationGutiérrez‐Angulo, M., González‐García, J. R., Meza‐Espinoza, J. P., Picos‐Cárdenas, V. J., Esparza‐Flores, M. A., López‐Guido, B., & Rivera, H. (2004) · Hematological Oncology · doi:10.1002/hon.734 · Cited by 6
Kajdic, A., Deuitch, N. T., Bresciani, E., Chong, S., Craft, K., Melo, M. S. D., Davis, J., Bashtawi, R., Patel, N., McReynolds, L. J., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025017808 · Cited by 6
Dual mechanism of inflammation sensing by the hematopoietic progenitor genome
Tran, V. L., Liu, P., Katsumura, K. R., Soukup, A. A., Kopp, A., Ahmad, Z. S., Mattina, A. E., Brand, M., Johnson, K. D., & Bresnick, E. H. (2025) · Science Advances · doi:10.1126/sciadv.adv3169 · Cited by 6
“Germline RUNX1 deficiency creates Familial Platelet Disorder with a predisposition to myeloid malignancy ( 22 , 23 ).”
Metadata
- Authors
- Song, W.-J., Sullivan, M. G., Legare, R. D., Hutchings, S., Tan, X., Kufrin, D., Ratajczak, J., Resende, I. C., Haworth, C., Hock, R., Loh, M., Felix, C., Roy, D.-C., Busque, L., Kurnit, D., Willman, C., Gewirtz, A. M., Speck, N. A., Bushweller, J. H., Li, F. P., Gardiner, K., Poncz, M., Maris, J. M., & Gilliland, D. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Brown University (US)
- University of Pennsylvania (US)
- Leicester Royal Infirmary (GB)
- St Vincent Hospital (US)
- Hôpital Maisonneuve-Rosemont (CA)
- University of Michigan (US)
- University of New Mexico (US)
- Dartmouth College (US)
- University of Virginia (US)
- Harvard University (US)
- Roosevelt Institute (US)
- Corresponding author
- Gilliland, D. Gary
- ORCID
- Venue
- Nature Genetics
- Published
- 1999-10
- Volume
- 23
- Issue
- 2
- Pages
- 166-175
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1739103212
- Cited by
- 1,100
- References
- 49
- Citations by year
- 2026: 9 · 2025: 23 · 2024: 27 · 2023: 32 · 2022: 29 · 2021: 36 · 2020: 46 · 2019: 33 · 2018: 26 · 2017: 61 · 2016: 54 · 2015: 35 · 2014: 30 · 2013: 33 · 2012: 53
- FWCI
- 25.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (7r29ai039536-04)
- National Cancer Institute (R01CA081932, R01-CA78545, R01 CA81932, R01CA078545)
- National Institute of Allergy and Infectious Diseases (R29 AI39536)
- Topics
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Blood disorders and treatments
- Keywords
- RUNX1, haploinsufficiency, autosomal dominant inheritance, missense mutations, megakaryopoiesis, megakaryocyte colony formation, platelet disorders, chromosome 21q, nonsense mutation, intragenic deletion
- MeSH terms
- Amino Acid Sequence, Base Sequence, Blood Platelets, Chromosome Mapping, Colony-Forming Units Assay, DNA Mutational Analysis, DNA-Binding Proteins, Family Health, Female, Genotype, Hematopoiesis, Heterozygote, Humans, Male, Megakaryocytes, Molecular Sequence Data, Mutation, Pedigree, Proto-Oncogene Proteins, RNA, Sequence Homology, Nucleic Acid, Thrombocytopenia, Transcription Factors, Leukemia, Myeloid, Acute, Sequence Deletion, Sequence Homology, Amino Acid, In Situ Hybridization, Fluorescence, Microsatellite Repeats, Genetic Predisposition to Disease, Reverse Transcriptase Polymerase Chain Reaction, Core Binding Factor Alpha 2 Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.